U.S. President Trump has announced a postponement of tariffs on certain countries until August, while concurrently issuing a stark warning of imposing tariffs as high as 200% on imported pharmaceutical products and a 50% tariff on copper goods. The precise timing for these measures remains unclear. Statistics reveal that in 2024, the total value of imported pharmaceuticals in the United States reached $212 billion, ranking it as the fifth largest import product. Notably, imports from Ireland, Singapore, and Belgium have shown the fastest growth rates. This decision could have profound implications for the global pharmaceutical supply chain and the copper industry.